Clinical Trials Logo

Clinical Trial Summary

The Leukemia and Lymphoma Society (LLS) has built a National Research Registry to evaluate real world experiences and medical outcomes for people with blood cancer, before, during, and after blood cancer treatments.


Clinical Trial Description

The LLS National Research Registry is a real-world experiences and outcomes research registry; a collection of patient information and medical data, over time, about people who have a particular disease or condition, or who receive a particular treatment. The LLS National Research Registry Protocol will: 1. Answer research questions using data collected from people with blood cancers. Such research involves analyses of subject profile information completed by subjects and medical records data. 2. Obtain permission from LLS National Research Registry research subjects to have Ciitizen, a third-party engaged by LLS, act as their proxy to retrieve full medical record data including images at no cost to research subjects. Note: Patient can choose to upload their medical records into their account, directly. 3. Obtain permission from LLS National Research Registry research subjects to share summary data with research partners (like academic researchers, advocacy groups, and pharmaceutical companies) that are advancing treatments for blood cancer. "Summary data" represents the important elements of medical record data, coded for research use, with personal identifiers like name, address, and phone number removed. 4. Obtain permission from LLS National Research Registry research subjects to be contacted from time to time, for them to provide updated medical information. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04806295
Study type Observational
Source Lymphoma and Leukemia Society
Contact Larry Saltzman, MD
Phone 844-696-7228
Email larry.saltzman@lls.org
Status Recruiting
Phase
Start date July 24, 2017
Completion date July 23, 2027

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Not yet recruiting NCT06455592 - Effect of APA on Sleep Quality in Children With Cancer From 5 to 16 Years N/A
Completed NCT03654404 - A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients N/A
Recruiting NCT06116032 - Immune Profiling for Cancer Immunotherapy Response
Recruiting NCT04955938 - A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms Phase 1
Recruiting NCT06119685 - IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers Phase 1/Phase 2
Not yet recruiting NCT05391490 - Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies Phase 1
Not yet recruiting NCT06469307 - Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Recruiting NCT05709522 - Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients
Completed NCT00186225 - Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors N/A
Active, not recruiting NCT05147311 - Positive Psychology Intervention In HSCT N/A
Recruiting NCT04372524 - Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
Completed NCT01957579 - A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies Phase 1
Completed NCT00185640 - Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies Phase 2
Withdrawn NCT04390542 - Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy N/A
Completed NCT04419623 - A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer Phase 1
Recruiting NCT05873205 - Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation Phase 2
Completed NCT00962494 - Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors Phase 2
Completed NCT00185796 - TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD Phase 2
Completed NCT04236063 - Rehabilitation Needs of the Malaysian Haematological Cancer Survivors